May 3, 2013
Harwood Feffer LLP (
) is investigating potential claims against the board of directors of Chemed Corporation ("Chemed" or the "Company") (NYSE: CHE), concerning whether the board has breached its fiduciary duties to shareholders.
May 2, 2013
, the U.S. Department of Justice (the "DOJ") sued Chemed and certain affiliates alleging that the Company systematically defrauded Medicare. According to the DOJ, the Company aggressively marketed intensive nursing care to patients who did not need it, and then improperly billed Medicare, sometimes for patients who never even received the care. The Company allegedly submitted fraudulent records and statements in support of these and other Medicare claims.
If the Company is found liable in the DOJ suit, it could be forced to pay back three times the amount of money it collected from Medicare, plus at least
in penalties for each individual false claim submitted to the government.
On this news, Chemed shares fell nearly 20%.
Our investigation concerns whether the Company board of directors has breached its fiduciary duties to shareholders, grossly mismanaged the Company, and/or committed abuses of control in connection with the foregoing.
If you own Chemed shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:
Robert I. Harwood, Esq.
Samuel K. Rosen, Esq.
Benjamin I. Sachs-Michaels, Esq.
Harwood Feffer LLP488 Madison Avenue
New York, New York
10022Phone Numbers: (877) 935-7400(212)935-7400Email:
has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (
) for more information about the firm.
Attorney Advertising. © 2013 Harwood Feffer LLP. The law firm responsible for this advertisement is Harwood Feffer LLP (
). Prior results do not guarantee or predict a similar outcome with respect to any future matter.